WuXi Biologics (Cayman) Inc. (WXIBF)

USD 1.9

(0.0%)

Market Cap (In USD)

7.8 Billion

Revenue (In USD)

17.03 Billion

Net Income (In USD)

3.39 Billion

Avg. Volume

487.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.3-3.92
PE
-
EPS
-
Beta Value
0.614
ISIN
KYG970081173
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Zhisheng Chen
Employee Count
-
Website
https://www.wuxibiologics.com
Ipo Date
2018-01-30
Details
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.